A Novel Carbon Monoxide-Releasing Molecule Fully Protects Mice from Severe Malaria

ABSTRACT Severe forms of malaria infection, such as cerebral malaria (CM) and acute lung injury (ALI), are mainly caused by the apicomplexan parasite Plasmodium falciparum. Primary therapy with quinine or artemisinin derivatives is generally effective in controlling P. falciparum parasitemia, but mortality from CM and other forms of severe malaria remains unacceptably high. Herein, we report the design and synthesis of a novel carbon monoxide-releasing molecule (CO-RM; ALF492) that fully protects mice against experimental CM (ECM) and ALI. ALF492 enables controlled CO delivery in vivo without affecting oxygen transport by hemoglobin, the major limitation in CO inhalation therapy. The protective effect is CO dependent and induces the expression of heme oxygenase-1, which contributes to the observed protection. Importantly, when used in combination with the antimalarial drug artesunate, ALF492 is an effective adjunctive and adjuvant treatment for ECM, conferring protection after the onset of severe disease. This study paves the way for the potential use of CO-RMs, such as ALF492, as adjunctive/adjuvant treatment in severe forms of malaria infection.

[1]  M. Romão,et al.  Towards improved therapeutic CORMs: understanding the reactivity of CORM-3 with proteins. , 2011, Current medicinal chemistry.

[2]  Douglas T. Golenbock,et al.  Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria , 2011, Proceedings of the National Academy of Sciences.

[3]  M. Galinski,et al.  The relevance of non-human primate and rodent malaria models for humans , 2011, Malaria Journal.

[4]  Gonçalo J. L. Bernardes,et al.  CORM-3 reactivity toward proteins: the crystal structure of a Ru(II) dicarbonyl-lysozyme complex. , 2011, Journal of the American Chemical Society.

[5]  Sung You Hong,et al.  Design, synthesis and biological evaluation of carbohydrate-functionalized cyclodextrins and liposomes for hepatocyte-specific targeting. , 2010, Organic & biomolecular chemistry.

[6]  C. John,et al.  Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria , 2010, Expert review of anti-infective therapy.

[7]  C. Janse,et al.  Sequestration and Tissue Accumulation of Human Malaria Parasites: Can We Learn Anything from Rodent Models of Malaria? , 2010, PLoS pathogens.

[8]  L. Otterbein,et al.  The therapeutic potential of carbon monoxide , 2010, Nature Reviews Drug Discovery.

[9]  M. Mota,et al.  Accumulation of Plasmodium berghei-Infected Red Blood Cells in the Brain Is Crucial for the Development of Cerebral Malaria in Mice , 2010, Infection and Immunity.

[10]  M. Mota,et al.  VEGF Promotes Malaria-Associated Acute Lung Injury in Mice , 2010, PLoS pathogens.

[11]  A. Baird,et al.  Microanatomy of the liver immune system , 2009, Seminars in Immunopathology.

[12]  Marcienne M Wright,et al.  Carbon monoxide rescues heme oxygenase-1-deficient mice from arterial thrombosis in allogeneic aortic transplantation. , 2009, The American journal of pathology.

[13]  C. Newton,et al.  Diagnosis and management of the neurological complications of falciparum malaria , 2009, Nature Reviews Neurology.

[14]  U. Schubert,et al.  Prospects of metal complexes peripherally substituted with sugars in biomedicinal applications. , 2009, Chemistry.

[15]  Stéphane Picot,et al.  Artesunate-erythropoietin combination for murine cerebral malaria treatment. , 2008, Acta tropica.

[16]  S. Croft,et al.  Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. , 2008, Acta tropica.

[17]  M. Alcaraz,et al.  Carbon monoxide-releasing molecules: a pharmacological expedient to counteract inflammation. , 2008, Current pharmaceutical design.

[18]  N. Oldham,et al.  Quantitative determination of lysozyme-ligand binding in the solution and gas phases by electrospray ionisation mass spectrometry. , 2007, Rapid communications in mass spectrometry : RCM.

[19]  M. Mota,et al.  Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria , 2007, Nature Medicine.

[20]  J. Nolan,et al.  A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. , 2006, Trends in parasitology.

[21]  G. Turner,et al.  Human cerebral malaria and the blood-brain barrier. , 2006, International journal for parasitology.

[22]  R. Jain,et al.  Pharmacological therapy for acute respiratory distress syndrome. , 2006, Mayo Clinic proceedings.

[23]  S. Ryter,et al.  CO as a cellular signaling molecule. , 2006, Annual review of pharmacology and toxicology.

[24]  A. Sepulveda,et al.  Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1–dependent pathway , 2005, The Journal of experimental medicine.

[25]  C. Newton,et al.  Pathogenesis, clinical features, and neurological outcome of cerebral malaria , 2005, The Lancet Neurology.

[26]  D. Stevenson,et al.  Determination of carbon monoxide (CO) in rodent tissue: effect of heme administration and environmental CO exposure. , 2005, Analytical biochemistry.

[27]  R. Snow,et al.  Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. , 2005, The Journal of infectious diseases.

[28]  S. Hay,et al.  The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.

[29]  Chris J Janse,et al.  A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. , 2004, Molecular and biochemical parasitology.

[30]  P. Wilairat,et al.  Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug Screening , 2004, Antimicrobial Agents and Chemotherapy.

[31]  P. Naughton,et al.  Cardioprotective Actions by a Water‐Soluble Carbon nMonoxide‐Releasing Molecule , 2003, Circulation research.

[32]  A. Trampuz,et al.  Clinical review: Severe malaria , 2003, Critical care.

[33]  L. Rénia,et al.  On the Pathogenic Role of Brain-Sequestered αβ CD8+ T Cells in Experimental Cerebral Malaria1 , 2002, The Journal of Immunology.

[34]  Jeffrey D. Sachs,et al.  A New Global Effort to Control Malaria , 2002, Science.

[35]  M. Zern,et al.  Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. , 2002, Frontiers in bioscience : a journal and virtual library.

[36]  Tzong-Shyuan Lee,et al.  Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice , 2002, Nature Medicine.

[37]  K. Matsumoto,et al.  Induction of heme oxygenase-1 suppresses venular leukocyte adhesion elicited by oxidative stress: role of bilirubin generated by the enzyme. , 1999, Circulation research.

[38]  B. Ryffel,et al.  Role of ICAM-1 (CD54) in the development of murine cerebral malaria. , 1999, Microbes and infection.

[39]  G. Grau,et al.  Profiles of cytokine production in relation with susceptibility to cerebral malaria. , 1993, Journal of immunology.

[40]  N. Hunt,et al.  Pathology of fatal and resolving Plasmodium berghei cerebral malaria in mice , 1992, Parasitology.

[41]  I. Clark,et al.  Breakdown of the blood-brain barrier in murine cerebral malaria , 1988, Parasitology.

[42]  G. Ashwell,et al.  A hepatic receptor of avian origin capable of binding specifically modified glycoproteins. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Canfield.  THE AMINO ACID SEQUENCE OF EGG WHITE LYSOZYME. , 1963, The Journal of biological chemistry.

[44]  S. Donegan,et al.  Artesunate versus quinine for treating severe malaria. , 2011, The Cochrane database of systematic reviews.

[45]  C. Dye,et al.  World Malaria Report, 2008. , 2008 .

[46]  Weltgesundheitsorganisation.  World malaria report , 2005 .

[47]  L. Rénia,et al.  On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria. , 2002, Journal of immunology.

[48]  B. Ryffel,et al.  Interferon-gamma is essential for the development of cerebral malaria. , 1997, European journal of immunology.

[49]  C. Newbold,et al.  Cerebral malaria: the sequestration hypothesis. , 1994, Parasitology today.